ETF Holdings Breakdown of MRSN

Stock Name	Mersana Therapeutics Inc
Ticker	MRSN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US59045L1061
LEI	529900VWD5VDZ7PVOS22

MRSN institutional holdings

The adjusted close for MRSN on 2025-11-12 was 8.87

The following institutional investment holdings of MRSN have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 3,040 USD 26,965 8.87

2025-11-12 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 3,040 0.3% USD 26,965 -0.2% 8.87

Total = 6,080 USD 53,930
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	3,040	USD 26,965	8.87
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	3,040 0.3%	USD 26,965 -0.2%	8.87
Total =	6,080	USD 53,930

News associated with MRSN

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $56.60 Average Target Price from Brokerages: Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Buy” by the six analysts that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in […] - 2025-08-27 02:07:07
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Rating of “Moderate Buy” from Brokerages: Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average […] - 2025-07-30 02:30:59
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $5.20: Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The […] - 2025-07-08 02:56:44
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $5.20: Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The […] - 2025-07-08 02:21:48
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.20 Average Price Target from Brokerages: Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given an average rating of “Buy” by the seven analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation […] - 2025-06-13 02:14:50
Bank of America Corp DE Has $1.36 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN): Bank of America Corp DE cut its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 3.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 953,952 shares of the company’s stock after selling 36,084 shares during the quarter. Bank […] - 2025-06-06 04:34:57
Millennium Management LLC Boosts Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN): Millennium Management LLC grew its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 206.4% during the fourth quarter, Holdings Channel reports. The fund owned 795,973 shares of the company’s stock after purchasing an additional 536,190 shares during the period. Millennium Management LLC’s holdings in Mersana Therapeutics were worth $1,138,000 as of […] - 2025-06-05 04:25:03
Short Interest in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Increases By 21.4%: Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 12,780,000 shares, an increase of 21.4% from the April 30th total of 10,530,000 shares. Approximately 11.7% of the shares of the stock are […] - 2025-06-04 05:22:49
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Two Sigma Advisers LP: Two Sigma Advisers LP trimmed its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 8.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 448,000 shares of the company’s stock after selling 38,800 shares during the period. Two Sigma Advisers LP’s holdings in Mersana Therapeutics were worth $641,000 at the end […] - 2025-06-04 04:48:48
Deutsche Bank AG Sells 756,449 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN): Deutsche Bank AG cut its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 47.4% during the fourth quarter, HoldingsChannel reports. The fund owned 839,724 shares of the company’s stock after selling 756,449 shares during the quarter. Deutsche Bank AG’s holdings in Mersana Therapeutics were worth $1,201,000 as of its most recent SEC filing. […] - 2025-05-26 05:04:45
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of “Buy” from Brokerages: Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy […] - 2025-05-21 05:09:00
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00: Mersana Therapeutics (NASDAQ:MRSN – Free Report) had its price target lifted by Truist Financial from $9.00 to $10.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock. MRSN has been the topic of several other reports. Guggenheim reissued a “buy” rating and issued a $5.00 […] - 2025-05-19 02:52:53
Barclays PLC Has $262,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN): Barclays PLC cut its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 63.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 182,711 shares of the company’s stock after selling 311,805 shares during the quarter. Barclays PLC’s holdings in Mersana Therapeutics were worth $262,000 at the end of the most recent reporting […] - 2025-05-12 04:30:56
Renaissance Technologies LLC Acquires 113,566 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN): Renaissance Technologies LLC lifted its holdings in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 23.0% during the 4th quarter, Holdings Channel reports. The firm owned 606,285 shares of the company’s stock after purchasing an additional 113,566 shares during the quarter. Renaissance Technologies LLC’s holdings in Mersana Therapeutics were worth $867,000 at the […] - 2025-05-02 05:54:49
XTX Topco Ltd Reduces Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN): XTX Topco Ltd trimmed its position in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 81.7% during the 4th quarter, HoldingsChannel reports. The firm owned 63,530 shares of the company’s stock after selling 283,725 shares during the period. XTX Topco Ltd’s holdings in Mersana Therapeutics were worth $91,000 as of its most recent filing with […] - 2025-04-30 05:31:04
ExodusPoint Capital Management LP Buys Shares of 194,153 Mersana Therapeutics, Inc. (NASDAQ:MRSN): ExodusPoint Capital Management LP bought a new position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 194,153 shares of the company’s stock, valued at approximately $278,000. ExodusPoint Capital Management LP […] - 2025-04-14 04:46:54
Los Angeles Capital Management LLC Sells 29,900 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN): Los Angeles Capital Management LLC lowered its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 15.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,760 shares of the company’s stock after selling 29,900 shares during the […] - 2025-03-05 08:46:57
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Price Target from Analysts: Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The […] - 2025-02-19 04:12:53
China Universal Asset Management Co. Ltd. Buys Shares of 26,194 Mersana Therapeutics, Inc. (NASDAQ:MRSN): China Universal Asset Management Co. Ltd. purchased a new stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 26,194 shares of the company’s stock, valued at approximately $37,000. A number of other hedge funds have also […] - 2025-02-05 06:46:56

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.